Amisulpride
- TRADE NAMES: Barhemsys (Acacia Pharma); Deniban (Sanofi-Aventis); Solian (Sanofi-Aventis)
- INDICATIONS: Prevention of postoperative nausea and vomiting (lower doses). Psychoses, schizophrenia (higher doses)
- CLASS: Antiemetic, Antipsychotic, Dopamine receptor antagonist
- HALF-LIFE: 4–5 hours (following intravenous infusion)
FDA APPROVAL DATE: 02/26/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Amiodarone, Bepridil, Cisapride, Disopyramide, Droperidol, Erythromycin, Flecainide, Levodopa, Ondansetron, Pentamidine, Procainamide, Quinidine, Sotalol, Sparfloxacin, Terfenadine, Thioridazine
Insufficient data to establish a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Approved by FDA for prevention of postoperative nausea and vomiting, February 2020.
Avoid use in patients with congenital long QT syndrome and in patients taking droperidol.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 03/07/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
